1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )TABLE 1:Demographic and descriptive statistics for patients imaged at each time categorized by therapeutic risk arm
Low Risk (n) Standard/High Risk (n) Post 1 IV-MTX 21 23 Post 4 IV-MTX 20 21 Post 7 IV-MTX 21 21 End of therapy 20 17 Gender Male 10 11 Female 12 12 Age at diagnosis (y, ±SD) 5.0 ± 2.7 9.2 ± 4.8
Note.—IV-MTX indicates intravenous methotrexate.